Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITIL-168 in advanced melanoma (DELTA-1)
NCT05050006Phase 2Terminated
- Sponsor
- Instil Bio, Inc.
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 3
01
Overview
A Phase 2 trial of ITIL-168 in cutaneous melanoma (CM), sponsored by Instil Bio, Inc.. Started Oct 2021; status: terminated.
02
Drugs
ITIL-168
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05050006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050006.